Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22763283 | 1.00 | NTRK1 (0.67) | NTRK1JAK2 | |
| SCHEMBL21588826 | 1.00 | NTRK1 (0.67) | NTRK1JAK2 | |
| SCHEMBL17830906 | 0.92 | NTRK1 (0.78) | NTRK1JAK2 | |
| SCHEMBL2599272 | 0.91 | NTRK1 (0.70) | NTRK1JAK2 | |
| SCHEMBL2599268 | 0.91 | NTRK1 (0.70) | NTRK1JAK2 | |
| SCHEMBL21911081 | 0.90 | NTRK1 (0.55) | NTRK1JAK2 | |
| SCHEMBL18783276 | 0.90 | NTRK1 (0.77) | NTRK1JAK2 | |
| SCHEMBL17820741 | 0.90 | NTRK1 (0.77) | NTRK1JAK2 | |
| SCHEMBL30013797 | 0.90 | NTRK1 (0.77) | NTRK1JAK2 | |
| SCHEMBL30152611 | 0.89 | NTRK1 (0.63) | NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597729-B2 | Tropomyosin receptor kinase inhibitor, preparation method therefor and use thereof | JIANGSU VCARE PHARMATECH CO., LTD. (CN) | 2023-03-07 | — | — | US | disclosed |
| CN-111918868-B | Diaryl macrocycles as protein kinase modulators | 正大天晴药业集团股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-3772516-B1 | TROPOMYOSIN RECEPTOR KINASE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU VCARE PHARMATECH CO LTD (CN) | 2022-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597729-B2 | Tropomyosin receptor kinase inhibitor, preparation method therefor and use thereof | MUSK, TPM4, TPM3 | NTRK1 21/4885JAK2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.